Full Text View
Tabular View
No Study Results Posted
Related Studies
A Novel Vaccine for the Treatment of MUC1-Expressing Tumor Malignancies
This study is not yet open for participant recruitment.
Study NCT00162500   Information provided by Hadassah Medical Organization
First Received: September 11, 2005   Last Updated: January 9, 2007   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Multiple Myeloma
Tumors
Additional conditions recognized in this trial
Neoplasms, Plasma Cell
More general conditions related to this trial
Blood Protein Disorders
Cardiovascular Diseases
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Paraproteinemias
Vascular Diseases
Interventions listed in this trial
Peptide Vaccine (MUC-1)
Sponsors listed in this trial
Hadassah Medical Organization
Vaxil Therapeutics Ltd.


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services